Amedeo Smart

Free Medical Literature Service

 

Amedeo

Neoplasms of the CNS
  Free Subscription

Articles published in
BMC Cancer
    March 2026
  1. XU Z, Yuan S, Li X, Chen H, et al
    ZCCHC4 drives glioma progression and serves as a prognostic biomarker.
    BMC Cancer. 2026 Mar 23. doi: 10.1186/s12885-026-15881.
    >> Share

  2. BALCI TOPUZ B, Ozturk Iyilikci M
    CALLY index provides improved prognostic stratification compared with other inflammation-based scores in glioblastoma treated with the stupp protocol.
    BMC Cancer. 2026 Mar 20. doi: 10.1186/s12885-026-15852.
    >> Share

  3. LI J, Tai Y, Pan B, Xiang L, et al
    Efficacy and prognostic factors of stereotactic radiosurgery versus whole-brain radiotherapy for brain metastases in small cell lung cancer: a systematic review and meta-analysis.
    BMC Cancer. 2026 Mar 18. doi: 10.1186/s12885-026-15871.
    >> Share

  4. HUANG J, Wang Q, Chen Y, Lin C, et al
    Regulatory mechanisms and functional analysis of cellular senescence-associated genes GAPDH, CCND1, and HBEGF in the immune microenvironment of meningioma.
    BMC Cancer. 2026 Mar 17. doi: 10.1186/s12885-026-15593.
    >> Share

    February 2026
  5. LIU M, Zhao K, Yang C, Sun G, et al
    Detection of IDH1.R132H mutant protein in plasma extracellular vesicles and its application in preoperative noninvasive precision diagnosis of glioma.
    BMC Cancer. 2026 Feb 28. doi: 10.1186/s12885-026-15810.
    >> Share

  6. ZHAO C, Huang R, Li X, Tang K, et al
    Radiomics of T2-weighted MRI for pretreatment prediction of prognosis and temozolomide chemosensitivity in glioma.
    BMC Cancer. 2026 Feb 17. doi: 10.1186/s12885-026-15726.
    >> Share

  7. ZHONG W, Wu S, Zhu R, Shi H, et al
    Optimal sequencing of brain radiotherapy and immunotherapy for patients with non-small cell lung cancer and driver gene-negative, asymptomatic brain metastases.
    BMC Cancer. 2026 Feb 15. doi: 10.1186/s12885-026-15706.
    >> Share

  8. SUCUOGLU ISLEYEN Z, Secmeler S, Sakin A, Cihan S, et al
    Evaluation of the efficacy and tolerability of bevacizumab-based treatments in recurrent primary brain tumors: a multicenter real-world Turkish Oncology Group (TOG) study.
    BMC Cancer. 2026 Feb 14. doi: 10.1186/s12885-026-15725.
    >> Share

  9. LI X, Li Z, Duan X, Liang Q, et al
    Machine learning-based radiopathomics ensemble model for predicting multiple molecular subtypes of adult diffuse glioma: a multicenter retrospective study.
    BMC Cancer. 2026 Feb 10. doi: 10.1186/s12885-026-15645.
    >> Share

    January 2026
  10. LI Y, Duan Y, Su Y, Zheng Z, et al
    Construction and internal assessment of an exploratory risk prediction model for psychological distress in brain tumor patients: a cross-sectional study.
    BMC Cancer. 2026 Jan 22. doi: 10.1186/s12885-026-15549.
    >> Share

  11. ZHANG C, Li S, Ren J, Wen X, et al
    Optimizing ribociclib dosing in breast cancer with brain metastasis patients using a physiologically based pharmacokinetic model.
    BMC Cancer. 2026 Jan 13. doi: 10.1186/s12885-026-15561.
    >> Share

  12. LI X, Lu T, Wang T, Zhuo J, et al
    MiR-218-5p inhibits glioma progression by targeting CKLF-like MARVEL transmembrane domain-containing 3.
    BMC Cancer. 2026 Jan 12. doi: 10.1186/s12885-026-15544.
    >> Share

    December 2025
  13. CHEN H, Liang W, Li Z, Bian C, et al
    Prognostic value of LPAR1 expression and methylation in low-grade gliomas: a meta-analysis of TCGA and CGGA datasets and functional validation.
    BMC Cancer. 2025 Dec 30. doi: 10.1186/s12885-025-15406.
    >> Share

  14. WANG J, Wang C, Sun Z, Zhang A, et al
    CXCL8-dependent recruitment of neutrophils by the tumor microenvironment drives poor prognosis in glioblastoma patients.
    BMC Cancer. 2025 Dec 26. doi: 10.1186/s12885-025-14698.
    >> Share

  15. BAI H, Liu Y, Ji C, Zhang Q, et al
    Mutation patterns and prognostic potentiality of homologous recombination repair genes in gliomas.
    BMC Cancer. 2025;25:1884.
    >> Share

  16. LIU J, Chen J, Chen L, Wang Y, et al
    Integrated single-cell and transcriptome sequencing data reveal the value of AOC1 in gliomas tumor microenvironment and prognosis.
    BMC Cancer. 2025 Dec 22. doi: 10.1186/s12885-025-15457.
    >> Share

  17. ALHALABI A, Abdo T, Hijazi A, Mohanna M, et al
    Factors associated with developing and surviving brain metastases in patients with breast cancer: a multi-center experience.
    BMC Cancer. 2025 Dec 19. doi: 10.1186/s12885-025-15422.
    >> Share

  18. JIANG X, Gui Y, Yang Y, Li J, et al
    Integrative bulk and single-cell transcriptomic profiling identifies core gene networks and potential therapeutic targets in glioma.
    BMC Cancer. 2025 Dec 13. doi: 10.1186/s12885-025-15454.
    >> Share

  19. WEI Y, Li R, Liu X, Shi Y, et al
    Clinical outcomes and predictive factors of immunotherapy efficacy in non-small-cell lung cancer brain metastases: a comparative study.
    BMC Cancer. 2025 Dec 7. doi: 10.1186/s12885-025-15327.
    >> Share

  20. DONG Y, Wang S, Wang C, Zhou J, et al
    Functional analysis and verification of GYG2 in oncolytic virus-infected glioma.
    BMC Cancer. 2025 Dec 6. doi: 10.1186/s12885-025-15407.
    >> Share

  21. FAN X, Dai J, Liu J, You G, et al
    Glioma-related epilepsy in patients with newly diagnosed and recurrent glioblastoma, IDH-wildtype: a study under the 2021 WHO CNS tumor classification.
    BMC Cancer. 2025 Dec 5. doi: 10.1186/s12885-025-15351.
    >> Share

  22. CAGDAS EK, Cagdas B
    LYN mutations in breast cancer: hypothesis-generating evidence for an association with central nervous system metastasis and domain-level insights.
    BMC Cancer. 2025 Dec 5. doi: 10.1186/s12885-025-15398.
    >> Share

  23. SARFRAZ Z, Ozair A, Bardhan M, Starosciak AK, et al
    Tucatinib, trastuzumab, and capecitabine with stereotactic radiosurgery in patients with brain metastases from HER-2 positive breast cancer (TUTOR): Study protocol for a multicenter phase 1 clinical trial.
    BMC Cancer. 2025 Dec 4. doi: 10.1186/s12885-025-15224.
    >> Share

  24. PARVIZI M, Nalbant OA, Kut E
    Prognostic relationship of peripheral blood-immune inflammatory index (C-PLAN) in patients with high-grade glioma.
    BMC Cancer. 2025 Dec 4. doi: 10.1186/s12885-025-15393.
    >> Share

  25. FLETCHER EV, Shard C, Boyle Y, Milligan CJ, et al
    Pharmacological targeting and characterization of Voltage-Gated Sodium Channels (VGSCs) expressed in the high-grade glioma microenvironment.
    BMC Cancer. 2025 Dec 2. doi: 10.1186/s12885-025-15319.
    >> Share

    November 2025
  26. ZHANG H, Gao M, Gao Z, Yao L, et al
    Identification and validation of SUN modification-related anti-PD-1 immunotherapy-resistance signatures to predict prognosis and immune microenvironment status in glioblastoma.
    BMC Cancer. 2025 Nov 29. doi: 10.1186/s12885-025-15345.
    >> Share

  27. HASELMANN J, Roohani S, Wasilewski D, Onken J, et al
    The interdisciplinary management of craniopharyngioma - practice patterns, outcomes, and insights.
    BMC Cancer. 2025 Nov 28. doi: 10.1186/s12885-025-14991.
    >> Share

  28. HUSEYINOGLU Z, Uysal E, Inan MA, Demirci T, et al
    Optimal qMSP cutoff value for MGMT promoter methylation in glioblastoma and its validation for clinical significance.
    BMC Cancer. 2025;25:1833.
    >> Share

  29. WEI J, Zou L, Liu Q, Xie Y, et al
    Identifying NDUFB2 as a prognostic biomarker for glioblastoma through an exploratory analysis of an anesthesia-related gene signature.
    BMC Cancer. 2025 Nov 27. doi: 10.1186/s12885-025-15312.
    >> Share

  30. LYU Q, Yuan H, Lin Z, Barcus R, et al
    A large scale multi-dataset investigation of brain metastases distribution based on primary cancer type.
    BMC Cancer. 2025;25:1821.
    >> Share

  31. YING L, Yangmei S, Qing X, Yuyu D, et al
    Construction and validation of a risk prediction model for symptom cluster distress in brain tumor patients: a cross-sectional study.
    BMC Cancer. 2025;25:1803.
    >> Share

  32. HAN R, Chi G, Sun D, Xu Z, et al
    Single-cell and spatial transcriptomics reveal lactylation-associated tumor cell clusters and define a prognostic risk model in glioblastoma.
    BMC Cancer. 2025 Nov 22. doi: 10.1186/s12885-025-15291.
    >> Share

  33. CHEN Q, Xiong J, Wang H, Xu Y, et al
    A nomogram for breast cancer brain metastasis patients after stereotactic radiotherapy.
    BMC Cancer. 2025;25:1784.
    >> Share

  34. WU H, Zhao T, Zhang W, Mi L, et al
    Comparative analysis of the outcomes of craniotomy and endoscopic resection for recurrent craniopharyngioma: a single institution study.
    BMC Cancer. 2025;25:1781.
    >> Share

  35. SANTOS MDC, Rodrigues NMV, Gibram F, Gouhie FA, et al
    Adjuvant chemoradiotherapy with procarbazine, lomustine, and vincristine (PCV) or temozolomide for 1p/19q Co-deleted anaplastic oligodendroglioma: a systematic review and network meta-analysis.
    BMC Cancer. 2025;25:1779.
    >> Share

  36. WANG Y, Chao Q, Lu X, Zhou Y, et al
    Clinical features and prognostic factors of ovarian cancer brain metastases from ovarian cancer: a retrospective multicenter study of 129 cases.
    BMC Cancer. 2025;25:1729.
    >> Share

  37. HUANG J, Tong S, Liu J, Hua S, et al
    Identification and validation of cuproptosis-related immune checkpoint expression for glioblastoma.
    BMC Cancer. 2025;25:1723.
    >> Share

    October 2025
  38. LU S, Xu L, Lan Y, Wang C, et al
    Study of plasma exosomal miRNAs as novel biomarkers for differentiating primary central nervous system lymphoma and glioblastoma.
    BMC Cancer. 2025;25:1657.
    >> Share

  39. ESTABILLO LL, Skaga E, Halldorsson S, Vik-Mo EO, et al
    Drug resistant glioblastoma stem cells exhibit enriched stemness signatures and share extracellular matrix overexpression.
    BMC Cancer. 2025;25:1655.
    >> Share

  40. HUANG M, Liu Y, Chen C, Cheng Y, et al
    Cyclic cytokines mediated the effect of immune cells on meningioma: a two-step, mediation mendelian randomization study.
    BMC Cancer. 2025;25:1633.
    >> Share

  41. XU L, Yu D, Li F, Ding X, et al
    A retrospective study of 30 cases evaluating the efficacy and safety of anlotinib plus Temozolomide for recurrent/residual glioma from a single center.
    BMC Cancer. 2025;25:1623.
    >> Share

  42. LI H, Li P, Zhu S, Hou W, et al
    Different detection rates of brain metastasis in different pathological types of lung cancer by (18)F-FAPI PET/CT.
    BMC Cancer. 2025;25:1620.
    >> Share

  43. ZHANG Q, Xu J, Deng S, Li X, et al
    Efficacy of brain radiotherapy combined with atezolizumab and platinum-doublet chemotherapy for advanced non-small-cell lung cancer with brain metastases: a pooled analysis.
    BMC Cancer. 2025;25:1568.
    >> Share

  44. MO F, Li Y, Dong C, Yang L, et al
    NFKBIE as a prognostic biomarker and therapeutic target for GBM: role in Hedgehog signaling activation.
    BMC Cancer. 2025;25:1512.
    >> Share

  45. ZUO C, Liu Y, Wang Z, Chen H, et al
    alpha-L-fucosidase isoenzymes (FUCA1/FUCA2) as prognostic markers in gliomas: a comprehensive study.
    BMC Cancer. 2025;25:1511.
    >> Share

  46. LI Y, Xu W, Zhao C, Zhang J, et al
    Survival risk stratification of 2021 WHO glioblastoma by MRI radiomics and biological exploration.
    BMC Cancer. 2025;25:1505.
    >> Share

  47. YANG Q, Wang Y, Wu J, Hu H, et al
    Preoperative prediction of pituitary neuroendocrine tumor consistency based on multiparametric MRI radiomics: a multicenter study.
    BMC Cancer. 2025;25:1501.
    >> Share

  48. CHEN X, Xiao X, Wang M, Mei T, et al
    Development and validation of a dynamic nomogram for predicting brain metastasis in stage III NSCLC patients undergoing definitive chemoradiotherapy.
    BMC Cancer. 2025;25:1500.
    >> Share

  49. LEISS SM, Wiestler B, Hou HX, Schmottermeyer D, et al
    Comorbidity burden in elderly high-grade glioma patients: impact on radiotherapy outcomes.
    BMC Cancer. 2025;25:1496.
    >> Share

  50. VARGHESE D, Collins J, Nordstrom B, Miranda M, et al
    Epidemiology and outcomes associated with brain metastases among patients with metastatic breast cancer - a cohort study in US electronic health record data.
    BMC Cancer. 2025;25:1475.
    >> Share

  51. PASYAR N, Rambod M, Zareinezhad S, Soltani A, et al
    The mediation role of hope and social support in the relationship between fatigue and burden in caregivers of patients with brain tumor.
    BMC Cancer. 2025;25:1491.
    >> Share

  52. YANG Z, Dou Z, Wang H, Hu Z, et al
    POLD3 knockdown effects on low-grade glioma: insights from bioinformatics and experimental validation.
    BMC Cancer. 2025;25:1489.
    >> Share

    September 2025
  53. DURRANI S, Al-Ghamdi AA, Al-Bugawi A, Al-Khammash A, et al
    Prognostic factors and survival outcome of brain metastases in breast cancer patients: a retrospective analysis.
    BMC Cancer. 2025;25:1455.
    >> Share

  54. WOJNICKI K, Wojtas B, Ciechomska IA, Kaza B, et al
    Shared and non-overlapping functions of RECQL4 and BLM helicases in chemotherapeutics-induced glioma cell responses.
    BMC Cancer. 2025;25:1434.
    >> Share

    August 2025
  55. LIN G, Zhuang Y, Lin F, Tan W, et al
    Volumetric amide-proton-transfer weighted imaging histogram analysis to differentiate pediatric high-grade and low-grade gliomas.
    BMC Cancer. 2025;25:1392.
    >> Share

  56. MILLER AR, Shah T, Strawser CN, Rivaldi A, et al
    MRD4U: A path to development for personalized liquid biopsy for children with central nervous system tumors.
    BMC Cancer. 2025;25:1365.
    >> Share

  57. ROY ME, Zgheib A, Eliopoulos N, Annabi B, et al
    A SORT1/EGFR molecular interplay as a prognostic biomarker in glioblastoma vasculogenic mimicry: implications in the transcriptional regulation of cancer stemness and drug resistance.
    BMC Cancer. 2025;25:1348.
    >> Share

  58. ZHANG F, Liu X
    Inhibition of c-Abl suppresses the proliferation, invasion and migration of glioma cells.
    BMC Cancer. 2025;25:1330.
    >> Share

  59. TAIWO R, Harary PM, Trinh TTH, Granucci M, et al
    Adaptive cohort design and LAT1 expression scale: study protocol for a Phase 2a trial of QBS72S in breast cancer brain metastases.
    BMC Cancer. 2025;25:1316.
    >> Share

    July 2025
  60. OLAYODE OO, Ogunoye BT, Oladeji EO, Olayinka OE, et al
    Cerebrospinal fluid Circulating Tumor DNA (ctDNA) as a biomarker for CNS metastases in Non-Small Cell Lung Cancer (NSCLC): a systematic review and meta-analysis comparing CSF ctDNA and traditional methods.
    BMC Cancer. 2025;25:1246.
    >> Share

  61. MINIERE HJM, Hormuth DA 2nd, Lima EABF, Farhat M, et al
    A data assimilation framework for predicting the spatiotemporal response of high-grade gliomas to chemoradiation.
    BMC Cancer. 2025;25:1239.
    >> Share

  62. LI F, Li Z, Xu H, Kong G, et al
    Prediction of 1p/19q state in glioma by integrated deep learning method based on MRI radiomics.
    BMC Cancer. 2025;25:1228.
    >> Share

  63. CHEN Z, Tang C, Ma X, Tian P, et al
    Efficacy and safety analysis of lorlatinib for ALK-positive advanced NSCLC: a multicentre real-world study in China.
    BMC Cancer. 2025;25:1216.
    >> Share

  64. SHAN X, Wang W, Zhang T, Liu W, et al
    Comparison the efficiency of whole brain radiotherapy and simultaneous integrated boost in small cell lung cancer with brain metastases.
    BMC Cancer. 2025;25:1210.
    >> Share

  65. HU Y, Zhi H, Zhang A, Lu S, et al
    Systematic analysis identifies TRIM22 as an oncogenic and immunological biomarker in glioma.
    BMC Cancer. 2025;25:1202.
    >> Share

  66. AMIN S, Amin P, Lin C
    Proton beam radiation therapy and the overall survival of adult and pediatric patients diagnosed with central nervous system tumors.
    BMC Cancer. 2025;25:1187.
    >> Share

  67. SHA X, Li J, Fang Y, Feng J, et al
    Enhanced tumor suppression in patient-derived temozolomide-resistant glioblastoma cells using a combination treatment of Olaparib and FK866.
    BMC Cancer. 2025;25:1174.
    >> Share

  68. XU W, Li Y, Zhang J, Zhang Z, et al
    Predicting the molecular subtypes of 2021 WHO grade 4 glioma by a multiparametric MRI-based machine learning model.
    BMC Cancer. 2025;25:1171.
    >> Share

  69. CHEN G, Shi X, Jiao R, Qian J, et al
    Clinical significance of NCOA4 in glioblastoma: diagnostic, prognostic, and therapeutic value.
    BMC Cancer. 2025;25:1151.
    >> Share

  70. ABYANEH R, Bordbar S, Moradi S, Molavizade S, et al
    Predictive molecular biomarkers of radiosensitivity in adult glioma: a narrative review.
    BMC Cancer. 2025;25:1146.
    >> Share

  71. ZHANG S, Wang Y, Jiang X, He R, et al
    Identification of dosimetric risk factors associated to lymphopenia in brain metastases patients with radiotherapy.
    BMC Cancer. 2025;25:1091.
    >> Share

  72. LI N, Jiang Y, Wang A, Jiang T, et al
    Sulforaphane induces cell morphology change and cell apoptosis by activating endoplasmic reticulum stress in glioblastoma.
    BMC Cancer. 2025;25:1050.
    >> Share

  73. NIU Y, Jia HB, Li XM, Huang WJ, et al
    Deep learning radiomics and mediastinal adipose tissue-based nomogram for preoperative prediction of postoperative? brain metastasis risk in non-small cell lung cancer.
    BMC Cancer. 2025;25:1133.
    >> Share

  74. KARAVOLIAS I, Karampinos KI, Kani ER, Drougkas K, et al
    Efficacy of vaccination therapy in newly diagnosed and recurrent glioblastoma patients: a meta-analysis.
    BMC Cancer. 2025;25:1027.
    >> Share

  75. YAO J, Zhang H, Gu Q, Sun X, et al
    PSMA5 as a modulator of glioblastoma senescence and prognosis.
    BMC Cancer. 2025;25:1079.
    >> Share

  76. LIU Z, Du X, Deng M, Chen Y, et al
    A retrospective propensity-matched study comparing whole-brain radiotherapy with simultaneous integrated boost to whole-brain radiotherapy alone for brain metastases.
    BMC Cancer. 2025;25:1121.
    >> Share

    June 2025
  77. LI H, Luo N, Fan C, Han T, et al
    Assessment of CDKN2A homozygous and heterozygous deletions in gliomas across multiple detection platforms.
    BMC Cancer. 2025;25:1007.
    >> Share

  78. WASILEWSKI D, Shaked Z, Fuchs A, Roohani S, et al
    Re-resection of brain metastases - outcomes of an institutional cohort study and literature review.
    BMC Cancer. 2025;25:973.
    >> Share

    May 2025
  79. MAHDIZADEH H, Izadpanah A, Nouri Y, Shams P, et al
    The safety and feasibility of multiple intrathecal injections of allogenic NK cells in pediatrics with refractory/recurrent brain tumors.
    BMC Cancer. 2025;25:952.
    >> Share

  80. WU S, Qiu Z, Shi H, Yu W, et al
    High-dose third-generation EGFR-TKIs combined with intrathecal pemetrexed in advanced EGFR-mutant NSCLC with leptomeningeal metastases following EGFR-TKI therapy.
    BMC Cancer. 2025;25:926.
    >> Share

  81. ZHANG M, Yang T, Qian Y
    APOL4-mediated intracellular cholesterol trafficking is essential for glioblastoma cell growth.
    BMC Cancer. 2025;25:906.
    >> Share

  82. DASGUPTA A, Mani S, Chatterjee A, Kannan S, et al
    Study protocol of short versus long-term levetiracetam in brain tumors (LIBRA): a phase 3 randomized controlled trial.
    BMC Cancer. 2025;25:911.
    >> Share

  83. WANG Y, Qiao S, Wang P, Li M, et al
    Copper's new role in cancer: how cuproptosis-related genes could revolutionize glioma treatment.
    BMC Cancer. 2025;25:859.
    >> Share

  84. HAJIKARIMLOO B, Mohammadzadeh I, Tos SM, Habibi MA, et al
    Machine learning in prediction of epidermal growth factor receptor status in non-small cell lung cancer brain metastases: a systematic review and meta-analysis.
    BMC Cancer. 2025;25:818.
    >> Share

    April 2025
  85. WANG P, Wang J, Fang Z, Chen Q, et al
    Novel metabolic subtypes in IDH-mutant gliomas: implications for prognosis and therapy.
    BMC Cancer. 2025;25:815.
    >> Share

  86. LIU J, Guan X, Gao S, Quan L, et al
    Novel insight of critical genes involved in breast cancer brain metastasis: evidence from a cross-tissue transcriptome association study and validation through external clinical cohorts.
    BMC Cancer. 2025;25:707.
    >> Share

  87. CHUNG MW, Tzeng CC, Huang YC, Wei KC, et al
    Neutrophil-to-lymphocyte ratio dynamics: prognostic value and potential for surveilling glioblastoma recurrence.
    BMC Cancer. 2025;25:709.
    >> Share

  88. ZHANG H, Wang Z, Qiao X, Wu J, et al
    Investigating potential drug targets for the treatment of glioblastoma: a Mendelian randomization study.
    BMC Cancer. 2025;25:654.
    >> Share

  89. YIN X, Lin X, Zhang G, Yin Y, et al
    Intensity-modulated proton therapy for hippocampal-sparing prophylactic cranial irradiation: a planning comparison with photon therapy.
    BMC Cancer. 2025;25:639.
    >> Share

  90. WANG S, Guo J, Xian X, Li M, et al
    Correction: Distinct 5-methylcytosine profiles of LncRNA in breast cancer brain metastasis.
    BMC Cancer. 2025;25:625.
    >> Share

  91. ZHENG J, Wang Z, Zhu H, Guo W, et al
    Impact of transducer arrays on deep-seated dosimetry in radiotherapy with concurrent TTFields for glioblastoma (extreme analysis).
    BMC Cancer. 2025;25:600.
    >> Share

    March 2025
  92. WANG S, Guo J, Xian X, Li M, et al
    Distinct 5-methylcytosine profiles of LncRNA in breast cancer brain metastasis.
    BMC Cancer. 2025;25:557.
    >> Share

  93. CAO P, Jia X, Wang X, Fan L, et al
    Deep learning radiomics for the prediction of epidermal growth factor receptor mutation status based on MRI in brain metastasis from lung adenocarcinoma patients.
    BMC Cancer. 2025;25:443.
    >> Share

  94. MAWHINNEY G, Higham H, Leedham S, Ansorge O, et al
    Study protocol for putting the 'Person' in the PiCTuRE: an exploratory sequential mixed methods-based design, exploring how precision medicine is implemented and experienced by people living with a primary tumour of the craniospinal axis.
    BMC Cancer. 2025;25:420.
    >> Share

  95. LIANG L, Lv W, Cheng G, Gao M, et al
    Impact of celastrol on mitochondrial dynamics and proliferation in glioblastoma.
    BMC Cancer. 2025;25:412.
    >> Share

  96. INGGAS MAM, Patel U, Wijaya JH, Otinashvili N, et al
    The role of temozolomide as adjuvant therapy in glioblastoma management: a systematic review and meta-analysis.
    BMC Cancer. 2025;25:399.
    >> Share

    February 2025
  97. SCHNEIDER M, Potthoff AL, Ahmadipour Y, Borger V, et al
    The ATLAS/NOA-29 study protocol: a phase III randomized controlled trial of anterior temporal lobectomy versus gross-total resection in newly-diagnosed temporal lobe glioblastoma.
    BMC Cancer. 2025;25:306.
    >> Share

  98. YANG X, Song Y, Xu R, Yang Y, et al
    Prophylactic cranial irradiation improved the prognosis in pT1-2N0M0 small cell lung cancers after complete resection: a retrospective real-world study.
    BMC Cancer. 2025;25:266.
    >> Share

  99. DEGUCHI S, Ohka F, Shiba Y, Yamaguchi J, et al
    Investigator-initiated phase I trial of an oligonucleotide therapeutic targeting long noncoding RNA TUG 1 for recurrent glioblastoma.
    BMC Cancer. 2025;25:251.
    >> Share

  100. WU D, Huang Y, Wang B, Zheng Q, et al
    A clinical model to predict brain metastases in resected early-stage non-small cell lung cancer.
    BMC Cancer. 2025;25:236.
    >> Share

  101. ZHANG C, Lv Z, Liang H, Hu F, et al
    Bioinformatics insights into ACSL1 and ACSL5: prognostic and immune roles in low-grade glioma.
    BMC Cancer. 2025;25:226.
    >> Share

  102. REZANEJAD-ASL P, Parhizkar Roudsari P, Rezaei N, Sharafkhah M, et al
    Pre-diagnostic risk factors for brain cancer incidence and survival: insights from the Golestan Cohort Study.
    BMC Cancer. 2025;25:210.
    >> Share

    January 2025
  103. ZHOU Z, Liu J, Yue Q, Chen L, et al
    Optimal treatment approach for intracranial germinoma: a systematic review and meta-analysis.
    BMC Cancer. 2025;25:26.
    >> Share

    December 2024
  104. LESUEUR P, Clarisse B, Lequesne J, Licaj I, et al
    Proton therapy versus conventional radiotherapy for the treatment of cavernous sinus benign meningioma, a randomized controlled phase III study protocol (COG-PROTON-01).
    BMC Cancer. 2024;24:1594.
    >> Share

  105. POURSAEED R, Mohammadzadeh M, Safaei AA
    Survival prediction of glioblastoma patients using machine learning and deep learning: a systematic review.
    BMC Cancer. 2024;24:1581.
    >> Share

  106. DENG G, Zhang Q, Fan J, Zhao C, et al
    Optimal intervention timing for craniocerebral radiotherapy in EGFR mutant lung adenocarcinoma patients with brain metastases.
    BMC Cancer. 2024;24:1571.
    >> Share

  107. ZHANG LY, Du HZ, Lu TT, Song SH, et al
    Long-term outcome of childhood and adolescent patients with craniopharyngiomas: a single center retrospective experience.
    BMC Cancer. 2024;24:1555.
    >> Share

  108. PRADO MB, Coelho BP, Iglesia RP, Alves RN, et al
    Prion protein regulates invasiveness in glioblastoma stem cells.
    BMC Cancer. 2024;24:1539.
    >> Share

  109. ZHANG X, Sun Q, Chen R, Zhao M, et al
    Efficacy and safety of combining anti-angiogenic therapy, radiotherapy, and PD-1 inhibitors in patients with driver gene-negative non-small cell lung cancer brain metastases: a retrospective study.
    BMC Cancer. 2024;24:1492.
    >> Share

  110. ROSSI J, Cavallieri F, Bassi MC, Venturelli F, et al
    To be or not to be: The dilemma over the prognostic role of epilepsy at presentation in patients with glioblastoma - a systematic review and meta-analysis.
    BMC Cancer. 2024;24:1488.
    >> Share

    November 2024
  111. HAJIKARIMLOO B, Habibi MA, Kooshki A, Alvani MS, et al
    Dabrafenib plus trametinib in low-grade versus high-grade gliomas: a systematic review and meta-analysis.
    BMC Cancer. 2024;24:1473.
    >> Share

  112. DAVE B, Tailor J
    Human stem cell models to unravel brain cancer.
    BMC Cancer. 2024;24:1465.
    >> Share

  113. LEE D, Lee E, Roh TH, Kim SH, et al
    Optimal timing of chemoradiation after resection or biopsy of glioblastomas: a nationwide population-based study.
    BMC Cancer. 2024;24:1450.
    >> Share

  114. GU J, Huang X, Zhang Y, Bao C, et al
    Cerebrospinal fluid IL-6 and IL-10 as promising diagnostic and therapeutic prognostic biomarkers for secondary central nervous system lymphoma.
    BMC Cancer. 2024;24:1443.
    >> Share

  115. HE Q, Wang W, Xu D, Xiong Y, et al
    Genetic association between mitochondrial DNA copy number and glioma risk: insights from causality.
    BMC Cancer. 2024;24:1439.
    >> Share

    October 2024
  116. WANG T, Li R, Liu S, Wu Q, et al
    The effects of immune checkpoint inhibitors vs. chemotherapy combined with brain radiotherapy in non-small cell lung cancer patients with brain metastases.
    BMC Cancer. 2024;24:1343.
    >> Share

  117. TONG Y, Wan X, Yin C, Lei T, et al
    In-depth exploration of the focus issues of TKI combined with radiotherapy for EGFR-mutant lung adenocarcinoma patients with brain metastasis: a systematic analysis based on literature metrology, meta-analysis, and real-world observational data.
    BMC Cancer. 2024;24:1305.
    >> Share

  118. WANG Y, Xu H, Sa Q, Li L, et al
    Development of graded prognostic assessment for breast Cancer brain metastasis incorporating extracranial metastatic features: a retrospective analysis of 284 patients.
    BMC Cancer. 2024;24:1262.
    >> Share

  119. GAO L, Zhang R, Zhang W, Lan Y, et al
    Integrated bioinformatics analysis and experimental validation on malignant progression and immune cell infiltration of LTBP2 in gliomas.
    BMC Cancer. 2024;24:1252.
    >> Share

    September 2024
  120. MOON HH, Park JE, Kim N, Kim YH, et al
    Prospective longitudinal analysis of imaging-based spatiotemporal tumor habitats in glioblastoma, IDH-wild type: implication in patient outcome using multiparametric physiologic MRI.
    BMC Cancer. 2024;24:1197.
    >> Share

  121. RUSSO R, Verdolotti T, Perna A, Ruscelli L, et al
    Central nervous system pediatric multi-disciplinary tumor board: a single center experience.
    BMC Cancer. 2024;24:1146.
    >> Share

  122. KHADHRAOUI E, Schmidt L, Klebingat S, Schwab R, et al
    Comparison of a new MR rapid wash-out map with MR perfusion in brain tumors.
    BMC Cancer. 2024;24:1139.
    >> Share

  123. BAO H, Chen Y, Meng Z, Chu Z, et al
    The causal relationship between CSF metabolites and GBM: a two-sample mendelian randomization analysis.
    BMC Cancer. 2024;24:1119.
    >> Share

  124. AFSORDEH N, Pournajaf S, Bayat H, Mohajerani F, et al
    Eslicarbazepine induces apoptosis and cell cycle arrest in C6 glioma cells in vitro and suppresses tumor growth in an intracranial rat model.
    BMC Cancer. 2024;24:1099.
    >> Share

    August 2024
  125. TIAN Y, Gao X, Yang X, Chen S, et al
    VEGFA contributes to tumor property of glioblastoma cells by promoting differentiation of myeloid-derived suppressor cells.
    BMC Cancer. 2024;24:1040.
    >> Share

  126. HOSOYA K, Ozasa H, Tanji M, Yoshida H, et al
    Performance status improvement and advances in systemic treatment after brain metastases resection: a retrospective single-center cohort study of non-small cell lung cancer patients.
    BMC Cancer. 2024;24:1030.
    >> Share

  127. YAN J, Guo C, Zheng H, Li Y, et al
    Noninvasive prediction of BRAF V600E mutation status of pleomorphic xanthoastrocytomas with MRI morphologic features and diffusion-weighted imaging.
    BMC Cancer. 2024;24:1022.
    >> Share

  128. WEI R, Zhou J, Bui B, Liu X, et al
    Glioma actively orchestrate a self-advantageous extracellular matrix to promote recurrence and progression.
    BMC Cancer. 2024;24:974.
    >> Share

  129. YU J, Fu J, Li Y, Hu G, et al
    Hypopituitarism after gamma knife radiosurgery for pituitary adenomas: long-term results from a single-center experience.
    BMC Cancer. 2024;24:963.
    >> Share

  130. YAO N, Qin Z, Chen M, Hu L, et al
    Effects of brain radiotherapy strategies on survival in the era of MRI for patients with limited stage small cell lung cancer.
    BMC Cancer. 2024;24:953.
    >> Share

  131. HIROSE T, Deguchi S, Yasui K, Inoue M, et al
    The indication of palliative whole-brain radiotherapy for patients with brain metastases: a simple prognostic scoring system in the era of stereotactic radiosurgery.
    BMC Cancer. 2024;24:940.
    >> Share

  132. WANG J, Zheng Q, Wang Y, Wang C, et al
    Dosimetric comparison of ZAP-X, Gamma Knife, and CyberKnife stereotactic radiosurgery for single brain metastasis.
    BMC Cancer. 2024;24:936.
    >> Share

    July 2024
  133. ZOTO MUSTAFAYEV T, Turna M, Bolukbasi Y, Tezcanli E, et al
    Clinical and radiological effects of Bevacizumab for the treatment of radionecrosis after stereotactic brain radiotherapy.
    BMC Cancer. 2024;24:918.
    >> Share

  134. LI Z, Wang J, Deng L, Zhai Y, et al
    Hippocampal avoidance whole-brain radiotherapy with simultaneous integrated boost in lung cancer brain metastases and utility of the Hopkins verbal learning test for testing cognitive impairment in Chinese patients: a prospective phase II study.
    BMC Cancer. 2024;24:899.
    >> Share

  135. DUAN Y, Wang Y, Zhang X, Huang J, et al
    Prevalence of dysphagia following posterior fossa tumor resection: a systematic review and meta?analysis.
    BMC Cancer. 2024;24:896.
    >> Share

  136. BICKERDIKE MJ, Nafia I, Bessede A, Chen CB, et al
    AT-0174, a novel dual IDO1/TDO2 enzyme inhibitor, synergises with temozolomide to improve survival in an orthotopic mouse model of glioblastoma.
    BMC Cancer. 2024;24:889.
    >> Share

  137. ROH YH, Park JE, Park SY, Cho YH, et al
    Assessment of imaging risks for recurrence after stereotactic radiosurgery for brain metastases (IRRaS-BM).
    BMC Cancer. 2024;24:866.
    >> Share

  138. LI X, Zhang Y, Ye Y, Tian S, et al
    Carbon-ion radiotherapy alone vs. standard dose photon radiation with carbon-ion radiotherapy boost for high-grade gliomas: a retrospective study.
    BMC Cancer. 2024;24:837.
    >> Share

  139. CHANG T, Zhang R, Gan J, Yang Y, et al
    Investigating distinct clinical features and constructing a nomogram model for survival probability in adults with cerebellar high-grade gliomas.
    BMC Cancer. 2024;24:836.
    >> Share

  140. LI YA, Zhao C, Ge JJ, Li C, et al
    Correction: Apatinib combined with temozolomide in diffuse midline glioma: a novel and effective therapy.
    BMC Cancer. 2024;24:829.
    >> Share

  141. XIE X, Luo C, Wu S, Qiao W, et al
    Recursive partitioning analysis for survival stratification and early imaging prediction of molecular biomarker in glioma patients.
    BMC Cancer. 2024;24:818.
    >> Share

  142. SU Y, Cheng R, Guo J, Zhang M, et al
    Differentiation of glioma and solitary brain metastasis: a multi-parameter magnetic resonance imaging study using histogram analysis.
    BMC Cancer. 2024;24:805.
    >> Share

  143. XIAO Y, Wu W, Liu F, Jia Y, et al
    The clinical significance of inflammatory mediators in predicting obesity and progression-free survival in patients with adult-onset Craniopharyngioma.
    BMC Cancer. 2024;24:799.
    >> Share

    June 2024
  144. LI YA, Zhao C, Ge JJ, Li C, et al
    Apatinib combined with temozolomide in diffuse midline glioma: a novel and effective therapy.
    BMC Cancer. 2024;24:754.
    >> Share

  145. LAKOMY R, Lojova M, Souckova L, Hynkova L, et al
    (11)C-methionine in the diagnostics and management of glioblastoma patients with rapid early progression: nonrandomized, open label, prospective clinical trial (GlioMET).
    BMC Cancer. 2024;24:736.
    >> Share

  146. LIU ZY, Tang F, Wang J, Yang JZ, et al
    Serum beta2-microglobulin acts as a biomarker for severity and prognosis in glioma patients: a preliminary clinical study.
    BMC Cancer. 2024;24:692.
    >> Share

    May 2024
  147. ZHANG LY, Guo W, Du HZ, Pan H, et al
    Brachytherapy in craniopharyngiomas: a systematic review and meta-analysis of long-term follow-up.
    BMC Cancer. 2024;24:637.
    >> Share

  148. AZIMI P, Yazdanian T, Ahmadiani A
    mRNA markers for survival prediction in glioblastoma multiforme patients: a systematic review with bioinformatic analyses.
    BMC Cancer. 2024;24:612.
    >> Share

  149. WANG J, Wang G, Cheng L, Zhu H, et al
    Preoperative peripheral inflammatory markers are predictors of postoperative central diabetes insipidus in craniopharyngioma patients: a retrospective study.
    BMC Cancer. 2024;24:572.
    >> Share

    April 2024
  150. KUMTHEKAR P, Lyleroehr M, Lacson L, Lukas RV, et al
    A qualitative evaluation of factors influencing Tumor Treating fields (TTFields) therapy decision making among brain tumor patients and physicians.
    BMC Cancer. 2024;24:527.
    >> Share

  151. LIU C, Liu F, Nie D, Xiao Y, et al
    Gut microbiota composition and metabolic characteristics in patients with Craniopharyngioma.
    BMC Cancer. 2024;24:521.
    >> Share

  152. DVORAKOVA K, Skarkova V, Vitovcova B, Soukup J, et al
    Expression of STAT3 and hypoxia markers in long-term surviving malignant glioma patients.
    BMC Cancer. 2024;24:509.
    >> Share

  153. SHI MX, Ding X, Tang L, Cao WJ, et al
    PROTAC EZH2 degrader-1 overcomes the resistance of podophyllotoxin derivatives in refractory small cell lung cancer with leptomeningeal metastasis.
    BMC Cancer. 2024;24:504.
    >> Share

  154. ORESKOVIC D, Madero Pohlen A, Cvitkovic I, Alen JF, et al
    Chronic hyperglycemia and intracranial meningiomas.
    BMC Cancer. 2024;24:488.
    >> Share

  155. DENG MY, da Silva AS, Goller PC, Konig L, et al
    Plasma extracellular vesicles in meningioma patients following radiotherapy as liquid biopsy- a prospective explorative biomarker study (ARO 2023-05/AG-NRO-07).
    BMC Cancer. 2024;24:449.
    >> Share

  156. KONG C, Yin X, Zou J, Ma C, et al
    The application of different machine learning models based on PET/CT images and EGFR in predicting brain metastasis of adenocarcinoma of the lung.
    BMC Cancer. 2024;24:454.
    >> Share

  157. CHEN M, Li R, Kong Y, Shi L, et al
    Rational and design of prophylactic cranial irradiation (PCI) and brain MRI surveillance versus brain MRI surveillance alone in patients with limited-stage small cell lung cancer achieving complete remission (CR) of tumor after chemoradiotherapy: a mu
    BMC Cancer. 2024;24:429.
    >> Share

    March 2024
  158. WANG G, Ren X, Li J, Cui R, et al
    High expression of RTEL1 predicates worse progression in gliomas and promotes tumorigenesis through JNK/ELK1 cascade.
    BMC Cancer. 2024;24:385.
    >> Share

  159. ZHANG W, Blank A, Kremenetskaia I, Nitzsche A, et al
    CD13 expression affects glioma patient survival and influences key functions of human glioblastoma cell lines in vitro.
    BMC Cancer. 2024;24:369.
    >> Share

  160. QI H, Hou Y, Zheng Z, Zheng M, et al
    Clinical characteristics and MRI based radiomics nomograms can predict iPFS and short-term efficacy of third-generation EGFR-TKI in EGFR-mutated lung adenocarcinoma with brain metastases.
    BMC Cancer. 2024;24:362.
    >> Share

  161. MA Y, Gong Y, Qiu Q, Ma C, et al
    Research on multi-model imaging machine learning for distinguishing early hepatocellular carcinoma.
    BMC Cancer. 2024;24:363.
    >> Share

  162. HUANG Y, Wu Z, Peng Z, Liu A, et al
    Hsa_circ_0004872 alleviates meningioma progression by sponging miR-190a-3p/PTEN signaling.
    BMC Cancer. 2024;24:345.
    >> Share

  163. ROUTMAN DM, Jusue-Torres I, Brown PD, Trifiletti DM, et al
    Pre-operative vs. post-operative stereotactic radiosurgery for operative metastatic brain tumors: study protocol for a phase III clinical trial.
    BMC Cancer. 2024;24:332.
    >> Share

  164. MENG J, Qian W, Yang Z, Gong L, et al
    p53/E2F7 axis promotes temozolomide chemoresistance in glioblastoma multiforme.
    BMC Cancer. 2024;24:317.
    >> Share

    February 2024
  165. SUN L, Jin X, Xie L, Xu G, et al
    Retraction Note: Swainsonine represses glioma cell proliferation, migration and invasion by reduction of miR-92a expression.
    BMC Cancer. 2024;24:275.
    >> Share

  166. QIAO W, Wang Y, Luo C, Wu J, et al
    Development of preoperative and postoperative models to predict recurrence in postoperative glioma patients: a longitudinal cohort study.
    BMC Cancer. 2024;24:274.
    >> Share

  167. KINO S, Kanamori M, Shimoda Y, Niizuma K, et al
    Distinguishing IDH mutation status in gliomas using FTIR-ATR spectra of peripheral blood plasma indicating clear traces of protein amyloid aggregation.
    BMC Cancer. 2024;24:222.
    >> Share

  168. BEN-ZION BERLINER M, Yust-Katz S, Lavie I, Goldberg Y, et al
    Central nervous system metastases in breast cancer patients with germline BRCA pathogenic variants compared to non-carriers: a matched-pair analysis.
    BMC Cancer. 2024;24:219.
    >> Share

  169. LI G, Ma L, Feng C, Yin H, et al
    MZ1, a BRD4 inhibitor, exerted its anti-cancer effects by suppressing SDC1 in glioblastoma.
    BMC Cancer. 2024;24:220.
    >> Share

  170. BOCCACINO JM, Dos Santos Peixoto R, Fernandes CFL, Cangiano G, et al
    Integrated transcriptomics uncovers an enhanced association between the prion protein gene expression and vesicle dynamics signatures in glioblastomas.
    BMC Cancer. 2024;24:199.
    >> Share

  171. SHIM YB, Oh BC, Lee EK, Park MH, et al
    Comparison of partitioned survival modeling with state transition modeling approaches with or without consideration of brain metastasis: a case study of Osimertinib versus pemetrexed-platinum.
    BMC Cancer. 2024;24:189.
    >> Share

  172. PHAM CP, Nguyen TTH, Do AT, Nguyen TK, et al
    A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam.
    BMC Cancer. 2024;24:176.
    >> Share

  173. LIAO L, Tang J, Hong Z, Jiang W, et al
    The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study.
    BMC Cancer. 2024;24:164.
    >> Share

    January 2024
  174. ZHANG X, Li Y, Zhang G, Ma C, et al
    Temporal trend in hospitalizations for malignant neoplasm and benign neoplasm: a nationwide study, China, 2004-2020.
    BMC Cancer. 2024;24:154.
    >> Share

  175. VAN TILBURG CM, Kilburn LB, Perreault S, Schmidt R, et al
    LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration.
    BMC Cancer. 2024;24:147.
    >> Share

  176. YU W, Zhou M, Niu H, Li J, et al
    Prognostic marker CXCL5 in glioblastoma polyformis and its mechanism of immune invasion.
    BMC Cancer. 2024;24:140.
    >> Share

  177. YAO B, Wang H, Wu X, Wang C, et al
    A system review of central nervous system tumors on children in China: epidemiology and clinical characteristics.
    BMC Cancer. 2024;24:138.
    >> Share

  178. HEUER S, Burghaus I, Gose M, Kessler T, et al
    PerSurge (NOA-30) phase II trial of perampanel treatment around surgery in patients with progressive glioblastoma.
    BMC Cancer. 2024;24:135.
    >> Share

  179. LU Y, Liao L, Du K, Mo J, et al
    Clinical activity and safety of sintilimab, bevacizumab, and TMZ in patients with recurrent glioblastoma.
    BMC Cancer. 2024;24:133.
    >> Share

  180. LIU JS, Cai YX, He YZ, Xu J, et al
    Spatial and temporal heterogeneity of tumor immune microenvironment between primary tumor and brain metastases in NSCLC.
    BMC Cancer. 2024;24:123.
    >> Share

  181. QIAN J, He Z, Wu Y, Li H, et al
    Analysis of the efficacy of upfront brain radiotherapy versus deferred radiotherapy for EGFR/ALK-positive non-small cell lung cancer with brain metastases: a retrospective study.
    BMC Cancer. 2024;24:117.
    >> Share

  182. YANG W, Han Y, He C, Zhong S, et al
    Association between psychiatric disorders and glioma risk: evidence from Mendelian randomization analysis.
    BMC Cancer. 2024;24:118.
    >> Share

  183. ZHU X, Liu Y, Guo W, Liang Q, et al
    Epidemiology, characteristics, and prognostic factors of lymphoplasmacyte-rich meningioma: a systematic literature review.
    BMC Cancer. 2024;24:110.
    >> Share

  184. LI L, Xia S, Zhao Z, Deng L, et al
    EMP3 as a prognostic biomarker correlates with EMT in GBM.
    BMC Cancer. 2024;24:89.
    >> Share

  185. ZUCHEGNA C, Leone S, Romano A, Porcellini A, et al
    KRAS is a molecular determinant of platinum responsiveness in glioblastoma.
    BMC Cancer. 2024;24:77.
    >> Share

  186. MASTALL M, Roth P, Bink A, Fischer Maranta A, et al
    A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol.
    BMC Cancer. 2024;24:82.
    >> Share

  187. BHASKARAN D, Savage J, Patel A, Collinson F, et al
    A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial.
    BMC Cancer. 2024;24:83.
    >> Share

  188. HUANG CY, Bai MH, Shen JW, Sun QQ, et al
    Anus preservation in low rectal adenocarcinoma based on MMR/MSI status (APRAM): a study protocol for a randomised, controlled, open-label, multicentre phase III trial.
    BMC Cancer. 2024;24:57.
    >> Share

  189. SUN Y, Liu P, Wang Z, Zhang H, et al
    Efficacy and indications of gamma knife radiosurgery for recurrent low-and high-grade glioma.
    BMC Cancer. 2024;24:37.
    >> Share

  190. CRUCITTA S, Pasqualetti F, Gonnelli A, Ruglioni M, et al
    IDH1 mutation is detectable in plasma cell-free DNA and is associated with survival outcome in glioma patients.
    BMC Cancer. 2024;24:31.
    >> Share

  191. MOHAJERANI F, Tehrankhah ZM, Rahmani S, Afsordeh N, et al
    CLEC19A overexpression inhibits tumor cell proliferation/migration and promotes apoptosis concomitant suppression of PI3K/AKT/NF-kappaB signaling pathway in glioblastoma multiforme.
    BMC Cancer. 2024;24:19.
    >> Share

  192. OUDIN A, Moreno-Sanchez PM, Baus V, Niclou SP, et al
    Magnetic resonance imaging-guided intracranial resection of glioblastoma tumors in patient-derived orthotopic xenografts leads to clinically relevant tumor recurrence.
    BMC Cancer. 2024;24:3.
    >> Share

  193. ZHAO S, Zhang M, Zhang Q, Wu J, et al
    Anlotinib alone or in combination with bevacizumab in the treatment of recurrent high-grade glioma: a prospective single-arm, open-label phase II trial.
    BMC Cancer. 2024;24:6.
    >> Share

    December 2023
  194. DAI L, Zhou P, Lyu L, Jiang S, et al
    Systematic analysis based on the cuproptosis-related genes identifies ferredoxin 1 as an immune regulator and therapeutic target for glioblastoma.
    BMC Cancer. 2023;23:1249.
    >> Share

  195. ZHANG K, Zhang T, Guo Z, Zhao F, et al
    Adding simultaneous integrated boost to whole brain radiation therapy improved intracranial tumour control and minimize radiation-induced brain injury risk for the treatment of brain metastases.
    BMC Cancer. 2023;23:1240.
    >> Share

  196. ADEGBOYEGA B, Joseph A, Alabi A, Omomila J, et al
    Patient reported outcomes following whole brain radiotherapy in patients with brain metastases in NSIA-LUTH Cancer Center.
    BMC Cancer. 2023;23:1233.
    >> Share

  197. BAI J, He M, Gao E, Yang G, et al
    Radiomic texture analysis based on neurite orientation dispersion and density imaging to differentiate glioblastoma from solitary brain metastasis.
    BMC Cancer. 2023;23:1231.
    >> Share

    November 2023
  198. SENRUNG A, Tripathi T, Yadav J, Janjua D, et al
    In vivo antiangiogenic effect of nimbolide, trans-chalcone and piperine for use against glioblastoma.
    BMC Cancer. 2023;23:1173.
    >> Share

  199. ZHANG Y, Wu X, Zhu J, Lu R, et al
    Knockdown of SLC39A14 inhibits glioma progression by promoting erastin-induced ferroptosis SLC39A14 knockdown inhibits glioma progression.
    BMC Cancer. 2023;23:1120.
    >> Share

    October 2023
  200. SONG Y, Lin S, Chen J, Dang J, et al
    First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis.
    BMC Cancer. 2023;23:1043.
    >> Share

  201. WEI D, Niu B, Zhai B, Liu XB, et al
    Expression profiles and function prediction of tRNA-derived fragments in glioma.
    BMC Cancer. 2023;23:1015.
    >> Share

  202. YANG XS, Zhu P, Xie RX, Chen PF, et al
    Tracking tumor alteration in glioma through serum fibroblast activation protein combined with image.
    BMC Cancer. 2023;23:1012.
    >> Share

  203. ROZATI H, Chen J, Williams M
    Overall survival following stereotactic radiosurgery for ten or more brain metastases: a systematic review and meta-analysis.
    BMC Cancer. 2023;23:1004.
    >> Share

  204. WANG Z, Cui Y, Wang F, Xu L, et al
    DNA methylation-regulated LINC02587 inhibits ferroptosis and promotes the progression of glioma cells through the CoQ-FSP1 pathway.
    BMC Cancer. 2023;23:989.
    >> Share

  205. VINCENT CA, Nissen I, Dakhel S, Hornblad A, et al
    Epigenomic perturbation of novel EGFR enhancers reduces the proliferative and invasive capacity of glioblastoma and increases sensitivity to temozolomide.
    BMC Cancer. 2023;23:945.
    >> Share

  206. ROBINSON SD, Samuels M, Jones W, Gilbert D, et al
    Shooting the messenger: a systematic review investigating extracellular vesicle isolation and characterisation methods and their influence on understanding extracellular vesicles-radiotherapy interactions in glioblastoma.
    BMC Cancer. 2023;23:939.
    >> Share

  207. MING Y, Luo C, Ji B, Cheng J, et al
    ARPC5 acts as a potential prognostic biomarker that is associated with cell proliferation, migration and immune infiltrate in gliomas.
    BMC Cancer. 2023;23:937.
    >> Share

    September 2023
  208. CHENG WY, Shen CC, Liang YJ, Chiao MT, et al
    Polymorphism at codon 31 of CDKN1A (p21) as a predictive factor for bevacizumab therapy in glioblastoma multiforme.
    BMC Cancer. 2023;23:886.
    >> Share

  209. HATTORI EY, Arakawa Y, Mineharu Y, Furukawa K, et al
    Seizure control by adding on other anti-seizure medication on seizure during levetiracetam administration in patients with glioma-related epilepsy.
    BMC Cancer. 2023;23:849.
    >> Share

  210. SHAN E, Cao YN, Zhang Y, Chen W, et al
    Integrated profiling identifies CACNG3 as a prognostic biomarker for patients with glioma.
    BMC Cancer. 2023;23:846.
    >> Share

  211. LIU Z, Hong X, Wang L, Ma Z, et al
    Radiomic features from multiparametric magnetic resonance imaging predict molecular subgroups of pediatric low-grade gliomas.
    BMC Cancer. 2023;23:848.
    >> Share

    August 2023
  212. MIRANDA J, Vazquez-Blomquist D, Bringas R, Fernandez-de-Cossio J, et al
    A co-formulation of interferons alpha2b and gamma distinctively targets cell cycle in the glioblastoma-derived cell line U-87MG.
    BMC Cancer. 2023;23:806.
    >> Share

  213. TAN C, Wei J, Li Z, Tian N, et al
    Circ_0021350 plays an oncogene role by regulating miR-1207-3p/PIK3R3 in glioblastoma.
    BMC Cancer. 2023;23:808.
    >> Share

  214. WANG X, Chen J, Lei Z, Chen H, et al
    Propensity score-matched analysis comparing hippocampus-avoidance whole-brain radiotherapy plus simultaneous integrated boost with hippocampus‑avoidance whole-brain radiotherapy alone for multiple brain metastases-a retrospective study in multiple i
    BMC Cancer. 2023;23:796.
    >> Share

  215. NEUTEL CLG, Viozzi I, Overduin CG, Rijpma A, et al
    Study protocol for a multicenter randomised controlled trial on the (cost)effectiveness of biopsy combined with same-session MR-guided LITT versus biopsy alone in patients with primary irresectable glioblastoma (EMITT trial).
    BMC Cancer. 2023;23:788.
    >> Share

  216. SOUSA N, Geiss C, Bindila L, Lieberwirth I, et al
    Targeting sphingolipid metabolism with the sphingosine kinase inhibitor SKI-II overcomes hypoxia-induced chemotherapy resistance in glioblastoma cells: effects on cell death, self-renewal, and invasion.
    BMC Cancer. 2023;23:762.
    >> Share

  217. ZHAO N, Weng S, Liu Z, Xu H, et al
    CRISPR-Cas9 identifies growth-related subtypes of glioblastoma with therapeutical significance through cell line knockdown.
    BMC Cancer. 2023;23:749.
    >> Share

  218. ZHONG K, Shi Y, Gao Y, Zhang H, et al
    First-line induction chemotherapy with high-dose methotrexate versus teniposide in patients with newly diagnosed primary central nervous system lymphoma: a retrospective, multicenter cohort study.
    BMC Cancer. 2023;23:746.
    >> Share

  219. LI J, Guo Q, Xing R
    Construction and validation of an immune infiltration-related risk model for predicting prognosis and immunotherapy response in low grade glioma.
    BMC Cancer. 2023;23:727.
    >> Share

    July 2023
  220. TAN Q, Wang Q, Jin S, Zhou F, et al
    Network Evolution Model-based prediction of tumor mutation burden from radiomic-clinical features in endometrial cancers.
    BMC Cancer. 2023;23:712.
    >> Share

  221. CHIEN CH, Lai CC, Chuang JY, Chu JM, et al
    Role of SH3GLB1 in the regulation of CD133 expression in GBM cells.
    BMC Cancer. 2023;23:713.
    >> Share

  222. WALTENBERGER M, Bernhardt D, Diehl C, Gempt J, et al
    Hypofractionated stereotactic radiotherapy (HFSRT) versus single fraction stereotactic radiosurgery (SRS) to the resection cavity of brain metastases after surgical resection (SATURNUS): study protocol for a randomized phase III trial.
    BMC Cancer. 2023;23:709.
    >> Share

  223. TAO R, Huang R, Yang J, Wang J, et al
    Comprehensive analysis of the clinical and biological significances of cholesterol metabolism in lower-grade gliomas.
    BMC Cancer. 2023;23:692.
    >> Share

  224. YUEYANG M, Yaqin H, Guolian X, Wenjian Z, et al
    Glioma angiogenesis is boosted by ELK3 activating the HIF-1[Formula: see text]/VEGF-A signaling axis.
    BMC Cancer. 2023;23:662.
    >> Share

    June 2023
  225. PENG Y, Liu H, Wu Q, Wang L, et al
    Integrated bioinformatics analysis and experimental validation reveal ISG20 as a novel prognostic indicator expressed on M2 macrophage in glioma.
    BMC Cancer. 2023;23:596.
    >> Share

  226. XUE Z, Wang J, Wang Z, Liu J, et al
    SLC25A32 promotes malignant progression of glioblastoma by activating PI3K-AKT signaling pathway.
    BMC Cancer. 2023;23:589.
    >> Share

  227. SUN S, Yang C, Wang K, Huang R, et al
    Molecular and clinical characterization of PTRF in glioma via 1,022 samples.
    BMC Cancer. 2023;23:551.
    >> Share

  228. WEI L, Pan M, Jiang Q, Hu B, et al
    Eukaryotic initiation factor 4 A-3 promotes glioblastoma growth and invasion through the Notch1-dependent pathway.
    BMC Cancer. 2023;23:550.
    >> Share

  229. FU M, Zhou Z, Huang X, Chen Z, et al
    Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map.
    BMC Cancer. 2023;23:544.
    >> Share

  230. HAO Z, Huajun S, Zhen G, Yu X, et al
    AQP8 promotes glioma proliferation and growth, possibly through the ROS/PTEN/AKT signaling pathway.
    BMC Cancer. 2023;23:516.
    >> Share

  231. BABAZADEH SM, Zolfaghari MR, Zargar M, Baesi K, et al
    Interleukin-24-mediated antitumor effects against human glioblastoma via upregulation of P38 MAPK and endogenous TRAIL-induced apoptosis and LC3-II activation-dependent autophagy.
    BMC Cancer. 2023;23:519.
    >> Share

    May 2023
  232. AKANDA MR, Ahn EJ, Kim YJ, Salam SMA, et al
    Analysis of stromal PDGFR-beta and alpha-SMA expression and their clinical relevance in brain metastases of breast cancer patients.
    BMC Cancer. 2023;23:468.
    >> Share

  233. CHEN Y, Ma F, Zhang Z, Guo Y, et al
    LncRNA-PVT1 was identified as a key regulator for TMZ resistance and STAT-related pathway in glioma.
    BMC Cancer. 2023;23:455.
    >> Share

  234. DUAN X, Yang B, Zhao C, Tie B, et al
    Prognostic value of preoperative hematological markers in patients with glioblastoma multiforme and construction of random survival forest model.
    BMC Cancer. 2023;23:432.
    >> Share

  235. LIU ZY, Lan T, Tang F, He YZ, et al
    ZDHHC15 promotes glioma malignancy and acts as a novel prognostic biomarker for patients with glioma.
    BMC Cancer. 2023;23:420.
    >> Share

  236. WANG X, Zhang H, Zhang M, Zhang X, et al
    Proteogenomic characterization of ferroptosis regulators reveals therapeutic potential in glioblastoma.
    BMC Cancer. 2023;23:415.
    >> Share

  237. ZOU R, Zhong X, Liang K, Zhi C, et al
    Elevated LILRB1 expression predicts poor prognosis and is associated with tumor immune infiltration in patients with glioma.
    BMC Cancer. 2023;23:403.
    >> Share

    April 2023
  238. THIVAT E, Casile M, Moreau J, Molnar I, et al
    Phase I/II study testing the combination of AGuIX nanoparticles with radiochemotherapy and concomitant temozolomide in patients with newly diagnosed glioblastoma (NANO-GBM trial protocol).
    BMC Cancer. 2023;23:344.
    >> Share

  239. ZHOU T, Zhu S, Xiong Q, Gan J, et al
    Intrathecal chemotherapy combined with systemic therapy in patients with refractory leptomeningeal metastasis of non-small cell lung cancer: a retrospective study.
    BMC Cancer. 2023;23:333.
    >> Share

  240. KELLER KM, Koetsier J, Schild L, Amo-Addae V, et al
    The potential of PARP as a therapeutic target across pediatric solid malignancies.
    BMC Cancer. 2023;23:310.
    >> Share

    March 2023
  241. WANG H, Xing R, Li M, Zhang M, et al
    Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: a retrospective study.
    BMC Cancer. 2023;23:289.
    >> Share

  242. CROUZEN JA, Petoukhova AL, Broekman MLD, Fiocco M, et al
    SAFESTEREO: phase II randomized trial to compare stereotactic radiosurgery with fractionated stereotactic radiosurgery for brain metastases.
    BMC Cancer. 2023;23:273.
    >> Share

  243. KING AL, Acquaye-Mallory AA, Vera E, Mendoza T, et al
    Feasibility and preliminary efficacy of a virtual reality intervention targeting distress and anxiety in primary brain tumor patients at the time of clinical evaluation: Study protocol for a phase 2 clinical trial.
    BMC Cancer. 2023;23:262.
    >> Share

  244. LIU X, Li Z, Sun J, Zhang Z, et al
    Interaction between PD-L1 and soluble VEGFR1 in glioblastoma-educated macrophages.
    BMC Cancer. 2023;23:259.
    >> Share

  245. ZHANG M, Liu X, Wang D, Ruan X, et al
    A novel cuproptosis-related gene signature to predict prognosis in Glioma.
    BMC Cancer. 2023;23:237.
    >> Share

  246. CAIN SA, Pope B, Mangiola S, Mantamadiotis T, et al
    Somatic mutation landscape in a cohort of meningiomas that have undergone grade progression.
    BMC Cancer. 2023;23:216.
    >> Share

  247. XU Z, Hao X, Wang Q, Yang K, et al
    Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy.
    BMC Cancer. 2023;23:206.
    >> Share

  248. GEURTS BS, Battaglia TW, van Berge Henegouwen JM, Zeverijn LJ, et al
    Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.
    BMC Cancer. 2023;23:205.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016